We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Teva Pharmaceutical has partnered with Modag for the development and licensing of the latter’s drug candidates, anle138b and sery433, for neurodegenerative disease.
MODAG announced the clinical trial initiation of a first-in-patient Phase 1b study for anle138b in patients with mild to moderate Parkinson´s Disease (PD).